EU/3/04/245: Orphan designation for the treatment of multiple myeloma

Aplidine

Table of contents

Overview

On 16 November 2004, orphan designation (EU/3/04/245) was granted by the European Commission to PharmaMar SA Sociedad Unipersonal, Spain, for aplidine for the treatment of multiple myeloma.

Key facts

Active substance
Aplidine
Intended use
Treatment of multiple myeloma
Orphan designation status
Positive
EU designation number
EU/3/04/245
Date of designation
16/11/2004
Sponsor
Phama Mar S.A. Sociedad Unipersonal
Polígono Industrial La Mina
Avda de los Reyes 1
E-28770 Colmenar Viejo
Madrid
Spain
Telephone: +34 91 84 66 000
Telefax: +34 91 84 66 001
E-mail: pharmamar@pharmamar.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating